Do you know that this stock will be up well over 300% over the next couple months?
For these Reasons:
Safe and effective drug
Consistent source of raw materials for product manufacture
cGMP manufacturing compliant
Manufacturing capacity to serve WORLDWIDE demand
Low cost of goods
Patent protection worldwide
Cash to support operations well into 2016 past all milestones
......I would add......
Huge facility ready to dominate production and distribution
No insider sales to mention
Covered by major analysts, sometimes favorably, sometimes not
Pivotal Trials well underway
Busy first quarter with news expected on Ampion
Optina announcement due any day
Further MRI data to view on the Super 7 and Strut and Stride
No competition in any regard for Ampion known or expected within five years
Potential huge market domestically and internationally for Ampion
Huge short load leading to near term short squeeze imminent
Are you ready for the $30s?
Agree, it's a reasonable guess, assuming they've done good DD but just did not publish the overall competitive landscape. Definitely extensions and/or off-label use will be a low barrier, should the clinicians continue to see many cases of significant improvement. Their (Citi's) conservative views are there mostly since the efficacy and potential patient population can't be properly assessed w/o completion of Phase III. Also, the claims of significant regeneration have to be completely discounted until definitive data is produced.
The DD teams I've been on debate pros/cons both by MOA, ITT, current and near-term potential therapeutics that could take market share. That may be part of the disparity between what MM thinks it's worth and what pharma is willing to pay. But, comparison to HA efficacy and costs (both COG and revenue) so far look great.
Unlikely AMPE will be sold for less than $20.00. With a strong licensing and partnership deal this could easily be a multi $Billion company in time.
The fact that RI now states he is here all day "defending this fine company" is laughable. if there were never such thing as yahoo stock message boards, the pps of AMPE would be, at the close of business yesterday, $5.32. The notion that this forum has any impact whatsoever further refutes this poster's claim that he was a securities "supervisor"..he has gone so far as to equate when bill appears to the pps going down, further comical thoughts...this individual also implies that just because we collectively believe he is a tool, that we are short ampe...I have gone so far as to post my trades..im very long this equity and hope it explodes further!!!.
you are correct in not getting in the muck of this individual, as they have become totally unglued..in any event I hope you prosper by owning shares here
don't want to be short now as momentun has shifted - citi group was in last week - there's going to be a buy out and potiential suitors are being lined up now - i believe the co will be sold this year with the takeout some
where in the $15-$20 range
Marginal source for valuation, reasonable starting place. Deeply discounted for obvious CYA reasons. The indication expansion potential for pain relief of joint inflammatory conditions alone makes for a quite a sizable market. Simple add on indications. OA of the hip, shoulder, elbow, etc. In the original Citi report (21/share) they DO mention this potential several times and state there conservatism.
This post is well worth sending to the top of the heap of usual do-do.
MS is just indexing, but Knoll and Talkot do serious DD. The latest heavy buying has to be institutional and is supported by renewed option activities. March 6 marks the approximated 20 wk timepoint for Phase II STRUT so this activity seems too early for a buildup to that event, based on past trading.
All current professional reports and data supports weak prospects for Optina commercial prospects, but a Phase IV allowability with a partner could change that. Or, it could just be a good pop on meeting statistical endpoints of Phase III. Either way, we all strongly suspect 3xAmpion will beat 3xSaline in STRUT.
But, it will indeed be interesting to see how many big investors are making big bets on AMPE. There was a serious exit after STEP, with new institutions just taking small positions.
The company has never provided guidance, like nearly every other biotech, pre-approval. Look at the Jefferies and Citi reports for estimated sales, then add 6-9 months due to the delay from STEP.
Someone just like you would think factual data is spam. Just like you, Funkmeisters abound, but the truth shall remain well above the fray of the Funk at all times.
Soon even someone just like you will realize this, and understand that an investor who was long this stock would greatly appreciate someone standing in defense of our fine company all day in the midst of haters just like you.
Ri66, this is the first time I have ever responded to you because I am afraid to make my hands dirty to write a response. I do not understand why you could not even tell that billwilliams836 is a bull and gives the insights on the company that nobody else can even come close. Look at the countless thumb down on your spam posts and you make yourself a clown on the board. I know I am stupid teaching an idiot a lesson and I will wash my hands right now.